Firm fixed price award
Ended Awarded Last action
- Contract number
- 75F40120F19036
- Awardee
-
Booz Allen Hamilton Inc. UEI JCBMLGPE6Z71 Part of Booz Allen Hamilton Holding Corporation
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $409,651
Award facts
- Contract value 100% obligated
- $409,651.32 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- PSC
- R499 Support- Professional: Other
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20857, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $409,651 |
About this award
Booz Allen Hamilton Inc. received a firm fixed-price contract award from the Food and Drug Administration (FDA) on July 26, 2020, with a ceiling value of $409,651.32 and an ultimate completion date of September 15, 2021. The contract, issued as a call against the Mission Oriented Business Integrated Services (MOBIS) blanket purchase agreement, supports a pipeline assessment for pharmacodynamic biomarkers in biosimilar development. Work is to be performed in Rockville, Maryland, under the oversight of FDA Contracting Officer Robert J. Parker. The award incorporates FDA's three-way-matching invoice clause for payment processing. This contract does not carry a small business set-aside designation.
The engagement leverages Booz Allen Hamilton's established relationship with the FDA, where the company maintains a substantial portfolio of task orders and contracts supporting regulatory science optimization, biomarker tracking, and electronic submission infrastructure. The pipeline assessment work aligns with the FDA's ongoing mission to advance the regulatory science framework supporting biosimilar product development, ensuring pharmacodynamic biomarkers are appropriately evaluated throughout the development lifecycle. The contract's modification structure indicates potential refinements to the statement of work during performance to accommodate evolving assessment requirements.
Quick answers
Who was awarded contract 75F40120F19036?
75F40120F19036 was awarded to Booz Allen Hamilton Inc. by Food and Drug Administration (Department of Health and Human Services) on July 26, 2020.
How much is contract 75F40120F19036 worth?
The government has obligated $409,651 on 75F40120F19036.
Is contract 75F40120F19036 an order under another contract?
Yes. 75F40120F19036 is a BPA call under GS23F9755H-HHSF223201510027B, a blanket purchase agreement, on Mission Oriented Business Integrated Services (MOBIS).
Was contract 75F40120F19036 competed?
The extent of competition for 75F40120F19036 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award